Pharmsynthez to establish production of hormonal drugs in Russia
Pharmsynthez (MICEX: LIFE), one of Russia’s leading drugmakers, plans to invest 3.2 billion roubles ($55 million) in the establishment of production of a range of innovative hormonal drugs, according to the company.
It is planned that the production will be established at the company’s facilities in the Tyumen region (Russian Siberia), reports The Pharma Letter’s local correspondent.
Vikram Punia, president of Pharmsynthez, said that currently Russia experiences a shortage of domestic production of drugs designed for the treatment hormonal diseases, while almost 100% of Russia’s needs in such drugs are provided by imports, being supplied by some global majors, operating in Russia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze